Does Rallies show 13F holders for ROIV?

Yes. Rallies tracks hedge fund and 13F ownership data for ROIV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ROIV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ROIV. It does not provide personalized investment advice.

ROIV (Roivant Sciences Ltd. Common Shares) Stock Analysis - Hedge Fund Holdings

Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of May 20, 2026, ROIV trades at $32.12 with a market cap of $20.43B and a P/E ratio of -118.03. ROIV moved +13.86% today. Year to date, ROIV is +28.64%; over the trailing twelve months it is +160.24%. Its 52-week range spans $8.73 to $30.33. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ROIV stock?

Hedge funds tracked by Rallies that own ROIV include Farallon Capital, Viking Global, Anchorage Capital, Blackbarn Capital, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Roivant Sciences Ltd. Common Shares.

ROIV Key Metrics

Key financial metrics for ROIV
Metric	Value
Price	$32.12
Market Cap	$20.43B
P/E Ratio	-118.03
EPS	$-0.24
Dividend Yield	0.00%
52-Week High	$30.33
52-Week Low	$8.73
Volume	7.05M
Avg Volume	0
Revenue (TTM)	$29.05M
Net Income	$-356.73M
Gross Margin	0.00%

Top Hedge Funds Holding ROIV

Farallon Capital holds 9.68M shares of ROIV, changed +26048.65% as of Mar 31, 2026.
Viking Global holds 6.65M shares of ROIV, changed +3.25% as of Mar 31, 2026.
Anchorage Capital holds 4.83M shares of ROIV, changed +0.00% as of Jun 30, 2025.
Blackbarn Capital holds 2.29M shares of ROIV, changed -25.91% as of Mar 31, 2026.
Orbimed Advisors holds 2.19M shares of ROIV, changed -19.30% as of Dec 31, 2025.

Latest ROIV News

Roivant Sciences Q4 EPS Tops Forecast, $770M Settlement Drives 9.9% Stock Jump — May 20, 2026
IMVT-1402 Shows 72.7% ACR20; Roivant Secures $2.25B Moderna Settlement — May 20, 2026
Roivant climbs as investors refocus on $950M Moderna settlement cash due July 8 — Apr 30, 2026
Roivant climbs as $4.3B cash position and buybacks spotlight pipeline momentum — Apr 27, 2026
Roivant slides as insider-sale filings hit tape ahead of Q3 FDA brepocitinib decision — Apr 24, 2026

Recent ROIV Insider Trades

Venker Eric sold 200.00K (~$5.92M) on Apr 20, 2026.
Gline Matthew sold 289.77K (~$8.45M) on Apr 16, 2026.
Humes Jennifer sold 13.54K (~$384.07K) on Apr 8, 2026.

ROIV Analyst Consensus

8 analysts cover ROIV: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.

Common questions about ROIV

Who owns ROIV stock?: Hedge funds tracked by Rallies that own ROIV include Farallon Capital, Viking Global, Anchorage Capital, Blackbarn Capital, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Roivant Sciences Ltd. Common Shares.
Does Rallies show 13F holders for ROIV?: Yes. Rallies tracks hedge fund and 13F ownership data for ROIV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ROIV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ROIV. It does not provide personalized investment advice.